Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 4, 2012, Pages 361-364

  Walkty, Andrew ^a,b,c   Baxter, Melanie ^c   Adam, Heather ^b,c   Karlowsky, James A ^b,c   Lagacé Wiens, Philippe ^b,c   Hoban, Daryl J ^b,c   Zhanel, George G ^a,c  

^a HEALTH SCIENCES CENTRE   (Canada)

^b Diagnostic Services of Manitoba Inc   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antimicrobial susceptibility; Multidrug resistant; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD SAMPLING; BROTH DILUTION; CANADA; EMERGENCY WARD; FEMALE; HOSPITAL; HUMAN; INTENSIVE CARE UNIT; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; SURGICAL WARD; URINALYSIS; WOUND;

ANTI-BACTERIAL AGENTS; CANADA; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84863784139     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.05.007     Document Type: Article

References (16)

1. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50:43-48.
2. Biedenbach D.J., Moet G.J., Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream isolates from the SENTRY antimicrobial surveillance program (1997-2002). Diagn Microbiol Infect Dis 2004, 50:59-69.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 22nd Informational supplement (M100-S22) 2012, CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition, M7-A7 2006, CLSI, Wayne, PA.
5. Gaynes R., Edwards J.R. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005, 41:848-854. and the National Nosocomial Infections Surveillance System.
6. Karlowsky J.A., Draghi D.C., Jones M.E., Thornsberry C., Friedland I.R., Sahm D.F. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003, 47:1681-1688.
7. Lodise T.P., Patel N., Kwa A., Graves J., Furuno J.P., Graffunder E., et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007, 51:3510-3515.
8. Master R.N., Clark R.B., Karlowsky J.A., Ramirez J., Bordon J.M. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Int J Antimicrob Agents 2011, 38:291-295.
9. Mathai D., Jones R.N., Pfaller M.A., The SENTRY Participant Group North America Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY antimicrobial surveillance program (North America). Diagn Microbiol Infect Dis 2001, 40:129-136.
10. Obritsch M.D., Fish D.N., MacLaren R., Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004, 48:4604-4610.
11. Rhomberg P.R., Jones R.N. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009, 65:414-426.
12. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:155-164.
13. Tam V.H., Rogers C.A., Chang K.T., Weston J.S., Caeiro J.P., Garey K.W. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010, 54:3717-3722.
14. Tumbarello M., Repetto E., Trecarichi E.M., Bernardini C., De Pascale G., Parisini A., et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 2011, 139:1740-1749.
15. Walkty A., DeCorby M., Nichol K., Mulvey M.R., Hoban D., Zhanel G., et al. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study. Diagn Microbiol Infect Dis 2008, 61:217-221.
16. Zhanel G.G., DeCorby M., Adam H., Mulvey M.R., McCracken M., Lagace-Wiens P., et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010, 54:4684-4693.